The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)

Marlies S. Wijsenbeek (Rotterdam, Netherlands), Marlies S. Wijsenbeek-Lourens, Merel L. Kimman, Adrienne Rotteveel, Xana van Jaarsveld, Stephanie S. Weinreich, Remy Mostard, Carmen D. Dirksen

Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Session: IPF: from pathogenesis to treatment I
Session type: Thematic Poster
Number: 793
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Marlies S. Wijsenbeek (Rotterdam, Netherlands), Marlies S. Wijsenbeek-Lourens, Merel L. Kimman, Adrienne Rotteveel, Xana van Jaarsveld, Stephanie S. Weinreich, Remy Mostard, Carmen D. Dirksen. The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 793

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015



Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Development of a national patient charter for idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016


The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016

Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018


The lived experience of idiopatic pulmonary fibrosis: A qualitative study
Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences
Year: 2016


Quality of life measures in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013


IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015


The efficacy of a walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). A pilot study
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015

Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012



Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


Quality of life in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 30s
Year: 2005

Quality of life of idiopathic pulmonary fibrosis patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017


Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey
Source: International Congress 2016 – IPF clinical
Year: 2016



Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020


Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Source: Breathe, 15 (2) 144; 10.1183/20734735.0016-2019
Year: 2019



The physical and psychological needs of patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016


A longitudinal study of anxiety and depression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013


Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015